Intellia Therapeutics, Inc.

Intellia Therapeutics is a clinical-stage biotechnology company developing in vivo genome editing treatments and engineered cell therapies. The company's primary focus is creating curative treatments for genetic diseases and cancers through CRISPR-based gene editing technology. Its pipeline includes NTLA-2001, currently in Phase 1 trials for transthyretin amyloidosis, and NTLA-2002, in Phase 1/2 development for hereditary angioedema. Beyond these proprietary programs, Intellia is advancing research into allogeneic CAR-T and NK cell therapies targeting various cancers and autoimmune conditions.

The company operates through multiple strategic partnerships to expand its therapeutic reach. Collaboration agreements span AvenCell Therapeutics for universal CAR-T development, Kyverna Therapeutics for CD19 CAR-T therapies in B-cell autoimmune diseases, ONK Therapeutics for engineered NK cell cancer therapies, and ReCode Therapeutics for genomic medicines addressing cystic fibrosis. These partnerships allow Intellia to pursue parallel therapeutic approaches while sharing development costs and risks.

Intellia maintains operations from its Cambridge, Massachusetts headquarters with approximately 403 full-time employees. The company was incorporated in Delaware in 2014 and trades on the Nasdaq exchange. As a pre-revenue clinical-stage entity, the company's advancement depends on successful trial outcomes and partnership milestones rather than established revenue streams.